42. Polyarteritis nodosa
14 clinical trials,   27 drugs   (DrugBank: 16 drugs),   26 drug target genes,   102 drug target pathways

Searched query = "Polyarteritis nodosa", "PAN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2019-003964-30-GB
(EUCTR)
22/10/202031/07/2020Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory vasculitis in adults and children.Biologics in refractory vasculitis (BIOVAS): A pragmatic, randomised, double-blind, placebo-controlled, modified-crossover trial of biologic therapy for refractory primary non-ANCA associated vasculitis in adults and children - Biologics in refractory vasculitis (BIOVAS) Non-ANCA associated vasculitides: 1.Giant cell arteritis (GCA)2.Takayasu’s arteritis (TA)3.Polyarteritis nodosa (PAN) or cutaneous polyarteritis unrelated to hepatitis B (CPAN)4.Relapsing polychondritis (RP)5.IgA vasculitis (IgAV)6.Cogan’s syndrome7.Non-infective cryoglobulinaemia8.Primary angiitis of central nervous system (PACNS)
MedDRA version: 21.1;Level: PT;Classification code 10047115;Term: Vasculitis;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Product Name: Infliximab
Product Code: N/A
INN or Proposed INN: Infliximab
Trade Name: Rituximab
Product Name: Rituximab
INN or Proposed INN: Rituximab
Trade Name: Tocilizumab
Product Name: Tocilizumab
Product Code: N/A
INN or Proposed INN: Tocilizumab
Cambridge University Hospitals NHS Foundation TrustNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
140Phase 2United Kingdom
2NCT03482479
(ClinicalTrials.gov)
February 4, 201922/3/2018Low Dose Naltrexone to Improve Physical Health in Patients With VasculitisLow Dose Naltrexone to Improve Physical Health in Patients With VasculitisEosinophilic Granulomatosis With Polyangiitis (EGPA);Churg-Strauss Syndrome (CSS);Giant Cell Arteritis;Granulomatosis With Polyangiitis;Microscopic Polyangiitis;Polyarteritis Nodosa;Takayasu ArteritisDrug: Naltrexone Hydrochloride;Other: Placebo ComparatorUniversity of PennsylvaniaNULLRecruiting18 YearsN/AAll36Phase 2United States
3NCT02939573
(ClinicalTrials.gov)
January 201718/10/2016A Randomized Multicenter Study for Isolated Skin VasculitisA Randomized Multicenter Study for Isolated Skin VasculitisPrimary Cutaneous Vasculitis;Cutaneous Polyarteritis Nodosa;IgA Vasculitis;Henoch-Schönlein PurpuraDrug: Colchicine;Drug: Dapsone;Drug: AzathioprineUniversity of PennsylvaniaNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);National Center for Advancing Translational Science (NCATS);Office of Rare Diseases (ORD)Recruiting18 YearsN/AAll90Phase 2United States;Canada;Japan
4EUCTR2013-004668-71-ES
(EUCTR)
13/10/201605/08/2016A study of treatment for polyarteritis nodosa in childrenAn Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN Childhood systemic polyarteritis nodosa (PAN)
MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept (Mycophenolate Mofetil)
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: Cyclophosphamide
Product Name: Cyclophosphamide
INN or Proposed INN: CYCLOPHOSPHAMIDE
University College LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 3Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden
5EUCTR2013-004668-71-IT
(EUCTR)
01/08/201614/07/2015A study of treatment for polyarteritis nodosa in childrenAn Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN Childhood systemic polyarteritis nodosa (PAN)
MedDRA version: 19.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept (Mycophenolate Mofetil)
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: Cyclophosphamide
Product Name: Cyclophosphamide
University College LondonNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
40Phase 3Portugal;Slovenia;Greece;Spain;Turkey;Italy;United Kingdom;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2013-004668-71-GB
(EUCTR)
25/09/201425/09/2014A study of treatment for polyarteritis nodosa in childrenAn Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN Childhood systemic polyarteritis nodosa (PAN)
MedDRA version: 17.0;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept (Mycophenolate Mofetil)
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: Cyclophosphamide
Product Name: Cyclophosphamide
University College LondonNULLNot RecruitingFemale: yes
Male: yes
40Phase 3Croatia;Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Germany;Netherlands;Sweden
7NCT00751517
(ClinicalTrials.gov)
September 200811/9/2008Cyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing VasculitidesCyclophosphamide Versus Methotrexate for Remission Maintenance in Systemic Necrotizing Vasculitides. A Randomized Controlled Trial.Wegener's Granulomatosis;Churg-Strauss Syndrome;Microscopic Polyangiitis;Polyarteritis NodosaDrug: Methotrexate;Drug: CyclophosphamideUniversity of ParmaNULLActive, not recruiting18 Years80 YearsBothPhase 2Italy
8NCT00647166
(ClinicalTrials.gov)
May 200826/3/2008Association Corticosteroid/Azathioprine in Microscopic Polyangiitis/ Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome)Evaluation of a New Treatment Strategy for Patients With Microscopic Polyangiitis, Polyarteritis Nodosa or Eosinophilic Granulomatosis With Polyangiitis (Churg Strauss Syndrome) Without Poor Prognosis FactorsMPA;PAN or EGPA With FFS=0;At Diagnosis or Within the First 15 Days Following Initiation of CorticosteroidsDrug: corticosteroid and azathioprine;Drug: corticosteroid and placeboAssistance Publique - Hôpitaux de ParisNULLCompleted18 YearsN/ABoth114Phase 3France
9NCT00307671
(ClinicalTrials.gov)
July 200527/3/2006Treatment of Necrotizing Vasculitides for Patients Older Than 65 YearsTreatment of Necrotizing Vasculitides for Patients Older Than 65 Years Comparison of Two Strategies Combining Steroids With or Without ImmunosuppressantsVasculitis;Wegener's Granulomatosis;Microscopic Polyangiitis;Churg-Strauss Syndrome;Polyarteritis NodosaDrug: prednisone, methylprednisolone,cyclophosphamides;Drug: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone;Drug: Mycophenolate mofetil,methotrexateAssistance Publique - Hôpitaux de ParisNULLCompleted65 YearsN/ABoth108Phase 4France
10NCT00006055
(ClinicalTrials.gov)
March 20005/7/2000Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune DiseasesPurpura, Schoenlein-Henoch;Graft Versus Host Disease;Anemia, Hemolytic, Autoimmune;Rheumatoid Arthritis;Churg-Strauss Syndrome;Hypersensitivity Vasculitis;Wegener's Granulomatosis;Systemic Lupus Erythematosus;Giant Cell Arteritis;Pure Red Cell Aplasia;Juvenile Rheumatoid Arthritis;Polyarteritis Nodosa;Autoimmune Thrombocytopenic Purpura;Takayasu ArteritisDrug: anti-thymocyte globulin;Drug: cyclophosphamide;Drug: cyclosporine;Drug: filgrastim;Drug: methylprednisolone;Drug: prednisone;Procedure: Autologous Peripheral Blood Stem Cell TransplantationFairview University Medical CenterNULLActive, not recruiting1 Year55 YearsBoth10N/AUnited States
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
11NCT00400075
(ClinicalTrials.gov)
July 199614/11/2006CHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis FactorsCHUSPAN PAN BP Treatment of Polyarteritis Nodosa and Microscopic Polyangiitis Without Poor-Prognosis Factors a Prospective Randomized Study in 125 PatientsPolyarteritis Nodosa;Microscopic PolyangiitisDrug: azathioprine;Drug: cyclophosphamideHospices Civils de LyonNULLActive, not recruiting15 Years90 YearsBoth124Phase 4Switzerland
12NCT00001457
(ClinicalTrials.gov)
September 19953/11/1999Lamivudine for Chronic Hepatitis BLamivudine for Chronic Hepatitis BChronic Hepatitis B;Chronic Hepatitis D;Glomerulonephritis;Polyarteritis NodosaDrug: LamivudineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NULLCompletedN/AN/ABoth60Phase 2United States
13EUCTR2013-004668-71-BE
(EUCTR)
12/04/2017A study of treatment for polyarteritis nodosa in childrenAn Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN Childhood systemic polyarteritis nodosa (PAN)
MedDRA version: 19.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept (Mycophenolate Mofetil)
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: Cyclophosphamide
Product Name: Cyclophosphamide
INN or Proposed INN: CYCLOPHOSPHAMIDE
INN or Proposed INN: CYCLOPHOSPHAMIDE
University College LondonNULLNAFemale: yes
Male: yes
40Phase 3Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Belgium;Poland;Croatia;Germany;Netherlands;Sweden
14EUCTR2013-004668-71-PT
(EUCTR)
16/02/2016A study of treatment for polyarteritis nodosa in childrenAn Open Label Randomised Controlled Trial of Mycophenolate Mofetil Versus Cyclophosphamide for the Induction of Remission of Childhood Polyarteritis Nodosa - MYPAN Childhood systemic polyarteritis nodosa (PAN)
MedDRA version: 18.1;Level: LLT;Classification code 10036026;Term: Polyarteritis nodosa of childhood;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: CellCept (Mycophenolate Mofetil)
Product Name: CellCept (Mycophenolate Mofetil)
INN or Proposed INN: Mycophenolate mofetil
Trade Name: Cyclophosphamide
Product Name: Cyclophosphamide
INN or Proposed INN: CYCLOPHOSPHAMIDE
University College LondonNULLNAFemale: yes
Male: yes
40Phase 3Portugal;Slovenia;Greece;Spain;Turkey;United Kingdom;Italy;Czech Republic;Poland;Belgium;Croatia;Germany;Netherlands;Sweden